These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7731020)

  • 1. Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
    Stein PD; Floyd DM; Bisaha S; Dickey J; Girotra RN; Gougoutas JZ; Kozlowski M; Lee VG; Liu EC; Malley MF
    J Med Chem; 1995 Apr; 38(8):1344-54. PubMed ID: 7731020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
    Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC
    J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
    Murugesan N; Gu Z; Stein PD; Bisaha S; Spergel S; Girotra R; Lee VG; Lloyd J; Misra RN; Schmidt J; Mathur A; Stratton L; Kelly YF; Bird E; Waldron T; Liu EC; Zhang R; Lee H; Serafino R; Abboa-Offei B; Mathers P; Giancarli M; Seymour AA; Webb ML; Hunt JT
    J Med Chem; 1998 Dec; 41(26):5198-218. PubMed ID: 9857090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor.
    Chan MF; Kois A; Verner EJ; Raju BG; Castillo RS; Wu C; Okun I; Stavros FD; Balaji VN
    Bioorg Med Chem; 1998 Dec; 6(12):2301-16. PubMed ID: 9925292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
    Kanda Y; Takahashi T; Araki Y; Konoike T; Mihara S; Fujimoto M
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1875-8. PubMed ID: 10969989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists.
    Kanda Y; Kawanishi Y; Oda K; Sakata T; Mihara SI; Asakura K; Kanemasa T; Ninomiya M; Fujimoto M; Konoike T
    Bioorg Med Chem; 2001 Apr; 9(4):897-907. PubMed ID: 11354672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.
    Stein PD; Hunt JT; Floyd DM; Moreland S; Dickinson KE; Mitchell C; Liu EC; Webb ML; Murugesan N; Dickey J
    J Med Chem; 1994 Feb; 37(3):329-31. PubMed ID: 8308857
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
    Murugesan N; Tellew JE; Gu Z; Kunst BL; Fadnis L; Cornelius LA; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Panchal B; Valentine MT; Chong S; Morrison RA; Carlson KE; Powell JR; Moreland S; Barrish JC; Kowala MC; Macor JE
    J Med Chem; 2002 Aug; 45(18):3829-35. PubMed ID: 12190306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity studies of endothelin leading to novel peptide ETA antagonists.
    Hunt JT; Lee VG; McMullen D; Liu EC; Bolgar M; Delaney CL; Festin SM; Floyd DM; Hedberg A; Natarajan S
    Bioorg Med Chem; 1993 Jul; 1(1):59-65. PubMed ID: 8081838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 May; 49(5):606-12. PubMed ID: 11383615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3355-68. PubMed ID: 11585441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis-sulfonamides as endothelin receptor antagonists.
    Boss C; Bolli MH; Weller T; Fischli W; Clozel M
    Bioorg Med Chem Lett; 2003 Mar; 13(5):951-4. PubMed ID: 12617928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.
    Bradbury RH; Bath C; Butlin RJ; Dennis M; Heys C; Hunt SJ; James R; Mortlock AA; Sumner NF; Tang EK; Telford B; Whiting E; Wilson C
    J Med Chem; 1997 Mar; 40(6):996-1004. PubMed ID: 9083490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
    Webb ML; Bird JE; Liu EC; Rose PM; Serafino R; Stein PD; Moreland S
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1124-34. PubMed ID: 7891325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional role of endothelin ETA and ETB receptors in venous and arterial smooth muscle.
    Lodge NJ; Zhang R; Halaka NN; Moreland S
    Eur J Pharmacol; 1995 Dec; 287(3):279-85. PubMed ID: 8991802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists.
    Fukami T; Nagase T; Fujita K; Hayama T; Niiyama K; Mase T; Nakajima S; Fukuroda T; Saeki T; Nishikibe M
    J Med Chem; 1995 Oct; 38(21):4309-24. PubMed ID: 7473559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Ohashi N; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3369-77. PubMed ID: 11585442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors.
    Krystek SR; Hunt JT; Stein PD; Stouch TR
    J Med Chem; 1995 Feb; 38(4):659-68. PubMed ID: 7861414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New selective and potent 5-HT(1B/1D) antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides.
    Liao Y; Böttcher H; Harting J; Greiner H; van Amsterdam C; Cremers T; Sundell S; März J; Rautenberg W; Wikström H
    J Med Chem; 2000 Feb; 43(3):517-25. PubMed ID: 10669578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.